Hepatitis A
73
1
4
52
Key Insights
Highlights
Success Rate
98% trial completion (above average)
Published Results
21 trials with published results (29%)
Research Maturity
52 completed trials (71% of total)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
1.4%
1 terminated out of 73 trials
98.1%
+11.5% vs benchmark
67%
49 trials in Phase 3/4
40%
21 of 52 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 52 completed trials
Clinical Trials (73)
A Study to Evaluate the 17-Year Immune Persistence of a Single Dose of Inactivated Hepatitis A Vaccine
Risk Factors and Outcomes of Hepatitis A in Children
Long-term Immunogenicity of L-HAV Vaccine Among Healthy Thai Children and Adolescents
Immunogenicity and Safety of I-HAV in Healthy Thai Children and Adolescents Lacking Protective Antibody After L-HAV
Comparative Evaluation of Oral Ursodeoxycholic Acid in Reducing Bilirubin Levels Among Patients With Acute Viral Hepatitis
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in HIV-infected People
Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents
Immunity With Acute Hepatits A
Effects of Aging on Primary and Secondary Vaccine Responses
Immunogenicity and Safety of Hepatitis A Among People Aged 18-50 Years Old
Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young Children
Phase IV Study of Concomitant Administration of the sIPV and HepA
Hepatitis B in Cystic Fibrosis and Latent Tuberculosis Respectively
Persistence of Hepatitis A Antibody in Healthy Adults ~32 Years Post Vaccination.
The Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines
Effectiveness of Booster With 1 or 2 Doses of HAV Vaccine Among HIV-infected Patients
To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24mons-15yrs
What is the Anti-HAV Seroprevalence of Travelers >60 Years or Having Lived in a Tropical Country for >5 Years